Humira (Adalimumab) for Hidradenitis suppurativa

Overview
Humira is a prescription medication approved by the Food and Drug Administration (FDA) to treat moderate to severe hidradenitis suppurativa in people age 12 and older. Humira is also known by its drug name, Adalimumab.

Humira is an immunomodulator, or in other words, a drug that modulates the immune system. It is considered a biologic disease-modifying antirheumatic drug (DMARD). Humira is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Humira is believed to work by neutralizing tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.

How do I take it?
After an initial loading dose, Humira is administered every week or every other week by subcutaneous injection.

Humira is available as a single-dose prefilled pen or single-dose prefilled syringe.

Side effects
The FDA-approved label for Humira lists common side effects including respiratory infections, headache, redness or irritation at injection sites, and rash.

Rare but serious side effects listed for Humira include severe allergic reactions, potentially fatal infections, new or worsening heart failure, lupus-like syndrome, demyelinating disease (such as multiple sclerosis), and increased risk for developing certain types of cancer such as lymphoma.

For more details about this treatment, visit:

Humira – AbbVie
https://www.humira.com/